All type of patients: 3 trials - EVEREST Clinical Status - EVEREST Outcome - Udelson
| tolvaptan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| tovalpan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Advanced heart failure: 2 trials - EVEREST Clinical Status - EVEREST Outcome
| tolvaptan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - EVEREST Clinical Status - EVEREST Outcome - Udelson
| tolvaptan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| tovalpan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
